BusinessBeiGene Presents Initial Phase 1b Data for BTK Inhibitor Zanubrutinib (BGB-3111) Combined with PD-1 Antibody Tislelizumab (BGB-A317) at the 59th American Society of Hematology Annual MeetingBy Nasdaq OMXDec 11, 2017, 3:00 PM UTC
BusinessBeiGene Presents Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) in Non-Hodgkin’s Lymphoma at the 59th American Society of Hematology Annual MeetingBy Nasdaq OMXDec 9, 2017, 5:15 PM UTC
BusinessBeiGene Presents Updated Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) Combined with GAZYVA® (Obinutuzumab) at the 59th American Society of Hematology Annual MeetingBy Nasdaq OMXDec 9, 2017, 2:00 PM UTC
BusinessBeiGene Announces Oral Presentation and Posters at the 59th American Society of Hematology Annual MeetingBy Nasdaq OMXNov 1, 2017, 1:02 PM UTC
